U p to 1.8 million patients in the United States experience refractory angina, 1 a debilitating condition that is common among patients with complex coronary artery disease. Many patients with chronic total occlusions (CTOs) are presented with few revascularization options, given that CTO percutaneous coronary intervention (PCI) is still limited to a few experienced operators in selected institutions and in light of fewer options for bypass surgery in the setting of a CTO. [2] [3] [4] In addition, the role of CTO PCI in the treatment of patients with CTOs and refractory angina remains poorly defined. Because persistent angina despite optimal medical therapy is the primary indication for CTO intervention in patients with stable ischemic heart disease, it is critical to better understand the angina burden in these patients and their health status improvements after CTO PCI. No previous studies have described the characteristics of these patients, their baseline health status, or their health status after CTO PCI. 5, 6 To address these gaps in knowledge, we analyzed patients with refractory angina symptoms undergoing CTO PCI in the OPEN-CTO study (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures), a multi-center study of consecutive CTO PCIs at 12 leading US centers. We examined the baseline health status, procedural success, and safety and long-term health status after CTO PCI to describe the health status change after CTO PCI in patients with medically refractory angina.
METHODS
The authors declare that all supporting data are available within the article.
Study Population
The OPEN-CTO study is a prospective, single-arm registry that enrolled consecutive patients with CTOs who underwent attempted CTO PCI at 12 US sites. Full study methods have been published previously. 7 Eligible patients were >18 years of age and had symptoms of ischemic heart disease, with Thrombolysis in Myocardial Infarction grade 0 flow and a lesion that was thought to have been present for ≥3 months. CTO PCI operators in OPEN-CTO were highly experienced and were required to have performed at least 100 CTO PCI procedures over a minimum of 2 years performing hybrid CTO PCI before participating in OPEN-CTO. Each participating site obtained institutional research board approval, and all patients provided informed consent.
Among 1000 patients enrolled in OPEN-CTO registry, we examined all patients who had refractory angina, defined as persistent angina, with a Seattle Angina Questionnaire Angina Frequency (SAQ AF) score of ≤90 points, 8 despite taking ≥3 antianginal medications (n=148). Procedural safety was assessed by assessing the incidence of major adverse cardiac and cerebral events (MACCE) and each individual component of MACCE, among patients with refractory angina.
As the focus of this study was to assess the health status change after CTO PCI in patients with refractory angina, the primary analytic cohort for 1-year health status analysis was restricted to the 132 patients who had baseline and 1-year SAQ follow-up (89.2%) (Figure 1 ).
Definitions
Refractory angina was defined as baseline angina SAQ AF ≤90 despite ≥3 antianginal medications (β-blockers, calcium channel blockers, long-acting nitrates, and ranolazine). Antianginal medication escalation in follow-up was defined as an additional antianginal agent at hospital discharge or an increase in the dose of a current medication at the time of discharge from the hospital. Technical success was defined as <50% residual stenosis and Thrombolysis in Myocardial Infarction 2 or 3 flow at the conclusion of the procedure and no side branch occlusion. 7 MACCE was defined as in-hospital death, myocardial infarction, emergent cardiac surgery, stroke, or clinical perforation. Clinical perforation was defined as any perforation requiring treatment. 7 All procedural angiograms were reviewed by an angiographic core laboratory (Saint Luke's Mid America Heart Institute, Kansas City, MO) using QAngio XA 7.3 (Medis Medical Imaging Systems, Leiden, The Netherlands) software. 
Assessment of Angina and Quality of Life
Health status was assessed at baseline and 12 months after CTO PCI with the coronary artery disease-specific SAQ. The SAQ is a 19-item questionnaire with a 4-week recall period that measures 5 domains of health status in patients with coronary artery disease: SAQ AF, angina stability, quality of life (SAQ QoL), physical limitation, and treatment satisfaction. 10, 11 Scores in each domain range from 0 to 100, with
WHAT IS KNOWN
• Refractory angina, despite maximal medical therapy, is a debilitating condition that is common among patients with coronary artery disease. • Many patients with refractory angina and chronic total occlusions are presented with few options for revascularization, and presence of a chronic total occlusion is the strongest predictor of incomplete revascularization.
WHAT THE STUDY ADDS
• Refractory angina (angina despite ≥3 antianginal medication) was present in 1 of 7 patients selected for chronic total occlusion percutaneous coronary intervention in OPEN-CTO (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures) registry.
• Successful chronic total occlusion percutaneous coronary intervention was associated with large and significant health status improvement.
• These data with significant clinical improvement in this highly symptomatic population could form the basis of future randomized trials focusing on the most symptomatic patients.
higher scores indicating fewer symptoms and better QoL. The SAQ has undergone extensive reliability and validity testing and is associated with long-term survival, hospitalization for acute coronary syndromes, and healthcare utilization among patients with coronary artery disease. 12, 13 Angina Frequency at baseline was captured with the SAQ AF domain, which has been shown to correlate closely with daily angina diaries. 14 The SAQ Summary Score (SS) summarizes patients' angina symptoms, function, and quality of life in a single score 15 and reflects the average of the SAQ AF, physical limitation, and QoL domains. Health status analyses were restricted to patients with complete 12-month follow-up health status.
Statistical Analyses
The demographic, clinical characteristics, baseline health status, procedural success, MACCE events, and long-term health status of patients with refractory angina were assessed in all participants. The characteristics of patients with successful and unsuccessful PCI were compared using Student t test for continuous variables and χ 2 tests for categorical variables. To account for potential bias attributable to those with missing follow-up data, we calculated a nonparsimonious propensity score with successful 1-year follow-up as the dependent variable. An inversely weighted propensity score was assigned to each responder to provide greater weight to the data of patients who were most like those without followup. All statistical analyses were performed with SAS version 9.4 (SAS Institute Inc, Cary, NC), and a 2-sided α level of 0.05 was used to determine statistical significance.
RESULTS
The baseline characteristics of patients with refractory angina are summarized in Table 1 . Mean age was 66.5±10.1, 64.2% of patients had prior history of coronary artery bypass grafting, 25.7% had history of heart failure, and 87.6% of patients had CCS III or IV angina. Procedural, lesion characteristics, and antianginal medication management among patients with refractory angina are summarized in Table 2 . On the basis of the appropriate use criteria, 64.2% were mapped appropriate, 11.5% mapped may be appropriate, 24.3% were unmappable, and 0% were rarely appropriate. Antianginal medication use at baseline included a β-blocker in 143 patients (96.6%), long-acting nitrates in 141 (95.3%), calcium channel blockers in 92 (62.2%), and ranolazine in 90 (60.8%). Mean baseline SAQ AF, SAQ QoL, and SAQ SS scores were 51.1±23.8 points, 35.3±21.2 points, and 47.2±17.9 points, respectively.
The in-hospital MACCE rate was 6.8% and included 4 myocardial infarction (2.7%) and 7 clinical perforations (4.7%) ( Table 3 ). There were no procedural deaths. Technical success was achieved in 120 (81.1%) patients at the index procedure. Including patients who underwent repeat successful procedures through 3-month follow-up (n=5), successful CTO PCI was achieved in 125 patients (84.5%). Physiologically complete revascularization was achieved in 97 (81.5%) patients.
Among 132 patients with complete 12-month health status follow-up, there was clinically significant improvement in all SAQ domains; SAQ AF, +32.0±27.8, SAQ QoL, +35.7±23.9 and SAQ SS, +32.1±20.1 ( Figure 2 ). When compared with patients with refractory angina who had unsuccessful CTO PCI, patients with successful CTO PCI experienced significantly larger increases in SAQ AF (+35.0±26.8 versus +18.8±28.9, P<0.01) and SAQ SS (+34.2±19.4 versus +22.5±20.8, P<0.01) and numerically larger increase in SAQ QoL (+37.3±24.3 versus +28.5±20.8, P=0.10) at 12-month follow-up (Table 4 ; Figure 3 ).
When compared with patients without refractory angina, patients with refractory angina had higher prevalence of hypertension, prior coronary artery bypass grafting, prior stenting, peripheral arterial disease, and chronic kidney disease (Table I in Supplement). Compared with patients without refractory angina, patients with refractory angina had higher J-CTO scores (Multicenter CTO Registry in Japan), longer lesion, and higher antianginal medication use; however, the rates of adverse events were similar (Table II in the Data Supplement). Patients with refractory angina had larger changes in SAQ AF, SAQ physical limitation, SAQ QoL, SAQ SS, and SAQ angina stability (Table III in the Data Supplement).
Among the 16 patients excluded from the health status analysis due to missing follow-up SAQ scores, 3 patients experienced MACCE (2 myocardial infarction and 1 clinical perforation) but no deaths. In a sensitivity analysis adjusting for the inverse of a propensity score for presence of complete 12-month health status data, results were not significantly different from the primary analysis. For example, SAQ SS change of patients who underwent successful procedure compared with patients who underwent unsuccessful procedure was +34.6± 20.0 versus +22.5±19.7 (P<0.01). Accordingly, only the unweighted analyses are presented.
Medical management after the index procedure is summarized in Table IV in the Data Supplement. The majority of patients with refractory angina underwent antianginal medication de-escalation during the followup period. There was no difference in rate of escalation /de-escalation of antianginal medications comparing patients who underwent successful to unsuccessful CTO PCI procedures.
DISCUSSION
Refractory angina is a debilitating condition characterized by ischemic chest pain despite maximal medical therapy. Many patients with refractory angina and CTOs are presented with few options for revascularization, and prior literature has indicated that the presence of a CTO is the strongest predictor of incomplete revascularization. 16 Accordingly, it is critical to understand the angina burden experienced by these patients and their health status outcomes after CTO PCI. In the first study to describe the angina burden experienced by patients with refractory angina undergoing CTO PCI, we found that refractory angina was present in 1 of 7 patients in the OPEN-CTO registry. These patients had profoundly impaired anginarelated QoL at baseline, and successful CTO PCI was performed with a high rate of success and was associated with large, clinically significant improvements in patientreported angina symptoms, physical function, and QoL. CTO PCI was safe in this population, with complication rates that were similar in comparison to those previously reported in the overall OPEN-CTO study population. 17 Refractory angina has been defined previously as chronic angina lasting >3 months, which cannot be controlled by medical therapy or coronary revascularization. 18 The true prevalence of refractory angina is unknown, but it has been estimated to affect as many as 1.8 million patients in the United States. 1 Similarly, in a Swedish study, 10% of patients referred for coronary angiography did not undergo revascularization despite severe limiting angina at baseline. 19 The proportion of these patients who have coronary CTOs is unclear, but the presence of a CTO has been shown to be the strongest predictor of incomplete revascularization in an analysis of a contemporary cohort of patients undergoing PCI. 16 Moreover, Williams et al 20 reported that the most frequent cause precluding revascularization was CTO in 69.7% of the patients who were deemed no revascularization option by the treating physician. Unfortunately, the diagnosis of refractory angina heavily depends on the revascularization options presented to the patient. Evidence suggests dramatic variability in the frequency of attempted CTO PCI across centers that are independently associated with operator experience and institutional bias. 21, 22 Accordingly, recent analyses of the National Cardiovascular Data Registry CathPCI data indicate that CTO PCI accounts for only 3.8% of PCI procedures, 23 despite the high prevalence of CTO lesions, which are present in nearly 1 in 5 patients undergoing coronary angiography. 22 As the CTO revascularization techniques continue to improve, with contemporary success rates of 80% to 90%, 17, 24, 25 more patients may be appropriate candidates for percutaneous revascularization of CTO lesions.
We observed significant health status impairment secondary to a high burden of angina symptoms at baseline, and a large, durable improvement in all SAQ domains present through 1 year after CTO PCI. The degree of health status improvement was larger than patients with refractory angina, and particularly robust among patients undergoing successful procedures, underscoring the potential impact of the procedure to alleviate symptoms and improve physical function. The degree of health status improvement in patients with refractory angina in OPEN-CTO was significantly larger than reported in previous randomized and observational studies that assessed QoL in all patients undergoing CTO PCI. 26, 27 For instance, the overall OPEN-CTO registry reported improvement in Although the magnitude of health status improvement in these studies was consistent with the SAQ improvement of 16.6 points in the SAQ AF domain after coronary artery bypass grafting, 29 we found even greater benefit among the highly symptomatic patients with refractory angina in OPEN-CTO. These findings underscore the importance of further studies of treatment strategies to manage refractory angina in patients with CTOs and suggest that these patients may be the most likely to benefit from PCI. Further studies are needed to develop strategies to identify these patients in routine clinical care and ensure that options for CTO revascularization are considered.
CTO PCI in patients with refractory angina was associated with a MACCE rate of 6.8% with no reported death which is lower than the overall OPEN-CTO registry. 17 Although this rate of MACCE is higher than elective PCI of lesions that are not chronically occluded, it is consistent with prior reports of non-CTO PCI in highrisk cohorts, such as saphenous vein graft intervention where an in-hospital mortality rate of 1.1% was observed. 30 Moreover, the procedural success rate was acceptable with 84.5% at 3 months despite high prevalence of predictors of lower success rate such as history of coronary artery bypass grafting (64.2%), peripheral arterial disease (28.4%), and higher J-CTO scores (mean J-CTO score of 2.6). 31, 32 Because the appropriateness of coronary revascularization is defined by careful consideration of the risk to benefit ratio, this population may pose a highly favorable risk-benefit ratio with higher risk, yet greater benefit compared with less symptomatic patients. These results should be considered in the context of the following potential limitations. First, this study examined a population of patients referred for CTO PCI at experienced centers. Accordingly, the prevalence of refractory angina among patients with CTOs in the broader population cannot be determined from this study, and these data may not be generalizable to all care settings. Second, 16 patients were excluded from the health status analyses because of missing follow-up SAQ scores at 12 months, and it is possible that these values were not missing at random and could have influenced the results. However, in a sensitivity analysis using the inverse of a propensity score for having complete health status follow-up, which gives larger weights to responders that are more similar to the patients lost to follow-up, results were unchanged from the primary analysis. Third, although the dosage of, and the titration of antianginal medications after PCI, were recorded, whether patients were on truly maximal tolerable dose of antianginal medications at baseline could not be systemically assessed. It is possible that some of the patients could have undergone further uptitration of these medications. However, we observed only 16.7% rate of medication titration in follow-up among the unsuccessful procedures, which suggests that most patients were already on maximal medical therapy at baseline. Fourth, the antianginal titration pattern before the CTO PCI was not collected. Therefore, the duration of maximal medical therapy before enrollment could not be determined. Fifth, as this is from a single-arm registry, the effect of CTO PCI compared with medical therapy could not be assessed, though the use of 3 antianginal medications represents a serious effort to medically manage patients. This should be addressed by future randomized studies. Finally, many patients are intolerant to some antianginal medications, and patients who were on <3 antianginal agents were not included in this study. It is possible that we excluded patients with refractory angina but who were not able to tolerate 3 agents.
In conclusion, we found that refractory angina was present in 1 of 7 patients selected for CTO PCI. These patients were highly symptomatic at baseline, and CTO PCI was performed with high rates of success and comparable complication rates to the broader population of patients undergoing CTO PCI. Given the large health status improvements reported through 12-month follow-up among these patients, they represent a group where the risk to benefit ratio is highly supportive of CTO PCI as therapeutic option. These large, durable health status improvements, in a highly symptomatic population, could form the basis of 
